Relay Therapeutics Inc (NASDAQ:RLAY) shares, rose in value, with the stock price down by -2.52% to the previous day’s close as strong demand from buyers drove the stock to $6.96.
Actively observing the price movement in the last trading, the stock closed the session at $7.14. Referring to stock’s 52-week performance, its high was $19.23, and the low was $5.95. On the whole, RLAY has fluctuated by -29.70% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.7, which is expected to increase to -$0.64 for fiscal year -$2.92 and then to about -$2.78 by fiscal year 2025. Data indicates that the EPS growth is expected to be -4.70% in 2025, while the next year’s EPS growth is forecast to be 4.80%.
According to the average forecast, sales growth in current quarter could jump down -69.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $200k, representing a decrease of -99.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RLAY’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RLAY currently trading nearly -17.29% and -24.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.65, while the 7-day volatility ratio is showing 5.38% which for the 30-day chart, stands at 6.05%. Furthermore, Relay Therapeutics Inc (RLAY)’s beta value is 1.65, and its average true range (ATR) is 0.52.
A comparison of Relay Therapeutics Inc (RLAY) with its peers suggests the former has fared considerably weaker in the market. RLAY showed an intraday change of -2.52% in last session, and over the past year, it shrunk by -58.82%%.
Data on historical trading for Relay Therapeutics Inc (NASDAQ:RLAY) indicates that the trading volumes over the past 10 days have averaged 1.21 million and over the past 3 months, they’ve averaged 1.11 million. According to company’s latest data on outstanding shares, there are 127.46 million shares outstanding.
Nearly 29.71% of Relay Therapeutics Inc’s shares belong to company insiders and institutional investors own 71.65% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.81 million shares as on Mar 15, 2024, resulting in a short ratio of 9.96. According to the data, the short interest in Relay Therapeutics Inc (RLAY) stood at 9.00% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 9.81 million. The stock has fallen by -36.78% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RLAY stock heading into the next quarter.
